Advances in medical management of overactive bladder.
Richelson
Elliott
E
Elliott
Daniel S
DS
D000279:Administration, Cutaneous; D000284:Administration, Oral; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D003408:Cresols / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D015337:Multicenter Studies as Topic; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D010665:Phenylpropanolamine; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012472:Salivation / Q000187:drug effects; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014481:United States; D014549:Urinary Incontinence / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D014554:Urination / Q000187:drug effects
D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin